Company

TScan Therapeutics, Inc.

TScan Therapeutics, Inc., based in Massachusetts, US, is a biopharmaceutical company developing T-cell receptor therapies for cancer.

About

Founded in 2018 and based in Waltham, Massachusetts, US, TScan Therapeutics develops T-cell receptor (TCR) therapies for hematological and solid tumors. The company was founded by Lea Hachigian and Tomasz Kula, and David Southwell is CEO. It raised USD 150 million in a private placement in April 2024, selling shares on the Nasdaq Global Select Market under the ticker TCRX, and raised USD 30 million in venture funding in December 2024.

4Funding rounds

9Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in